Publications, Clinical Trial Results, Pending Approvals, and Milestone Payments - Research Report on Merck, Johnson & Johnson, Allergan, Amarin, and Isis Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, October 23, 2013 NEW YORK, October 23, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Merck & Co., Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ), Allergan, Inc. (NYSE: AGN), Amarin Corporation plc (NASDAQ: AMRN), and Isis Pharmaceuticals, Inc. (NASDAQ: ISIS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Merck & Co., Inc. Research Report On October 14, 2013, Merck & Co., Inc. (Merck) and Endocyte, Inc. (Endocyte) announced the online publication of results from the randomized Phase II PRECEDENT trial for vintafolide in the Journal of Clinical Oncology (JCO), the official journal of the American Society of Oncology. The results from the Phase II PRECENDENT trial, as reported in JCO online, showed that administration of vintafolide plus pegylated liposomal doxorubicin (PLD) versus PLD alone in women with platinum-resistant ovarian cancer resulted in a median progression-free survival (PFS) of 5.0 months compared to 2.7 months for those treated with PLD alone. "Targeting the folate receptor, which is expressed on the majority of epithelial ovarian cancers, is a potentially promising strategy, especially when combined with a companion diagnostic that is designed to identify patients who are most likely to respond to the treatment, a hallmark of personalized medicine," said R. Wendel Naumann, M.D., Associate Director of Gynecologic Oncology at Carolina HealthCare System's Levine Cancer Institute, Charlotte, N.C. The Full Research Report on Merck & Co., Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/430d_MRK] -- Johnson & Johnson Research Report On October 17, 2013, Johnson & Johnson announced that its Board of Directors has declared a Q4 2013 cash dividend of $0.66 per share on the Company's common stock. According to the Company, the dividend is payable on December 10, 2013, to shareholders of record at the close of business on November 26, 2013, with an ex-dividend date of November 22, 2013. The Full Research Report on Johnson & Johnson - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/07a8_JNJ] -- Allergan, Inc. Research Report On October 7, 2013, Allergan, Inc. (Allergan) announced that the results from a non-randomized, case-controlled study recently published in the PLOS ONE scientific online journal suggests cost recovery and long-term savings for morbidly obese patients undergoing Laparoscopic Adjustable Gastric Banding (LAGB or banding) and Laparoscopic Roux-enY Gastric Bypass (LRYGB or bypass) procedures. "This analysis continues to support existing evidence that bariatric surgery - especially gastric banding - can cut healthcare spending on obesity and related co-morbidities quite significantly for patients, payers and the overall healthcare system," said John Dixon, MBBS, PhD, FRACGP, FRCP Edin, Baker IDI Heart and Diabetes Institute, Melbourne, Australia. "This data proves that there is a cost benefit to including bariatric surgery as a core component of health insurance plans and providing easier access to patients." The Full Research Report on Allergan, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/182a_AGN] -- Amarin Corporation plc Research Report On October 16, 2013, Amarin Corporation plc (Amarin) announced that the FDA Endocrinologic and Metabolic Drugs Advisory Committee has voted 9 to 2 against approval of Vascepa capsules for use as an adjunct to diet and exercise and in combination with a statin in the treatment of adult patients with high triglycerides with mixed dyslipidemia and coronary heart disease (CHD) or a CHD risk equivalent. The Company informed that the FDA intends to make its decision regarding the approval of the ANCHOR Supplemental New Drug Application (sNDA) on December 20, 2013, Prescription Drug User Fee Act (PDUFA) goal date for the sNDA. The Full Research Report on Amarin Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/7cf9_AMRN] -- Isis Pharmaceuticals, Inc. Research Report On October 16, 2013, Isis Pharmaceuticals, Inc. (Isis) announced that it has earned a $10 million milestone payment from Biogen Idec, in relation to the selection and advancement of ISIS-DMPK[RX] to treat myotonic dystrophy type I (DM1). "In less than two years, we discovered and advanced ISIS-DMPK[Rx] into development, and we plan to begin human clinical studies next year," said B. Lynne Parshall, COO at Isis. "In our preclinical studies, we and our collaborators, Drs. Charles Thornton and Thurman Wheeler at the University of Rochester, have been able to target the toxic RNA with antisense, remove the toxic RNA and restore normal cell function. We look forward to working with Biogen Idec to move this program into human clinical trials," added C. Frank Bennett, Ph.D., Senior Vice President of Research at Isis. The Full Research Report on Isis Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/fcfc_ISIS] ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. AnalystsCorner.com SOURCE Analysts' Corner Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
Publications, Clinical Trial Results, Pending Approvals, and Milestone Payments - Research Report on Merck, Johnson & Johnson,
Press spacebar to pause and continue. Press esc to stop.